The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism

被引:41
|
作者
Su, Hengchuan [1 ]
Gu, Yanyun [2 ]
Li, Fengying [2 ]
Wang, Qidi [2 ]
Huang, Baoxing [1 ]
Jin, Xiaolong [3 ]
Ning, Guang [2 ]
Sun, Fukang [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Urol, Shanghai 200030, Peoples R China
[2] Shanghai Jiao Tong Univ, Dept Endocrinol, Clin Ctr Shanghai Endocrine & Metab Dis, Ruijin Hosp,Sch Med, Shanghai 200030, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pathol, Shanghai 200030, Peoples R China
来源
PLOS ONE | 2013年 / 8卷 / 04期
关键词
MTOR PATHWAY; DIAGNOSIS; APOPTOSIS; INCREASES; SECRETION; CANCER; FORMS;
D O I
10.1371/journal.pone.0062399
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: To date, the available non-invasive remedies for primary aldosteronism are not satisfactory in clinical practice. The phosphoinositide 3-kinase (PI3Ks)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway is essential for tumorigenesis and metastasis in many types of human tumors, including renal cancer, adrenal carcinoma and pheochromocytoma. The possibility that this pathway is also necessary for the pathogenesis of primary aldosteronism has not yet been explored. To answer this question, we investigated the activity of the PI3K/AKT/mTOR signaling pathway in normal adrenal glands (NAGs), primary aldosteronism (PA) patients and NCI-H295R cells. Methodology/Principal Findings: Between January 2005 and December 2011, we retrospectively reviewed the records of 45 patients with PA. We compared clinical characteristics (age, gender and biochemical data) and the expression of phospho-AKT (p-AKT), phospho-mTOR (p-mTOR), phospho-S6 (p-S6) and vascular endothelial growth factor (VEGF) by immunohistochemical staining and western blotting, analyzing 30 aldosterone-producing adenomas (APAs), 15 idiopathic hyperaldosteronism (IHA) tissues and 12 NAGs following nephrectomy for renal tumors (control group). Compared with the control group, most of the PA patients presented with polydipsia, polyuria, resistant hypertension, profound hypokalemia, hyperaldosteronemia and decreased plasma renin activity. Compared with normal zona glomerulosa, the levels of p-AKT, p-mTOR, p-S6 and VEGF were significantly upregulated in APA and IHA. No significant differences were found between APA and IHA in the expression of these proteins. Additionally, positive correlations existed between the plasma aldosterone levels and the expression of p-AKT and p-mTOR. In vitro studies showed that mTOR inhibitor rapamycin could inhibit cell proliferation in NCI-H295R cells in a dose-and time-dependent manner. Furthermore, this inhibitor also decreased aldosterone secretion. Conclusions: Our data suggest that the PI3K/AKT/mTOR signaling pathway, which was overactivated in APA and IHA compared with normal zona glomerulosa, may mediate aldosterone hypersecretion and participate in the development of PA.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
    Antonino Glaviano
    Aaron S. C. Foo
    Hiu Y. Lam
    Kenneth C. H. Yap
    William Jacot
    Robert H. Jones
    Huiyan Eng
    Madhumathy G. Nair
    Pooyan Makvandi
    Birgit Geoerger
    Matthew H. Kulke
    Richard D. Baird
    Jyothi S. Prabhu
    Daniela Carbone
    Camilla Pecoraro
    Daniel B. L. Teh
    Gautam Sethi
    Vincenzo Cavalieri
    Kevin H. Lin
    Nathalie R. Javidi-Sharifi
    Eneda Toska
    Matthew S. Davids
    Jennifer R. Brown
    Patrizia Diana
    Justin Stebbing
    David A. Fruman
    Alan P. Kumar
    Molecular Cancer, 22
  • [22] PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
    Leiphrakpam, Premila D.
    Are, Chandrakanth
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [23] The PI3K/AKT/mTOR signaling pathway: Implications in the treatment of breast cancer
    Andreopoulou E.
    Current Breast Cancer Reports, 2011, 3 (1) : 63 - 74
  • [24] The Cardioprotection of the Insulin-Mediated PI3K/Akt/mTOR Signaling Pathway
    Yao, Hong
    Han, Xiangyang
    Han, Xiuzhen
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (06) : 433 - 442
  • [25] Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer
    Akbarzadeh, Maryam
    Mihanfar, Ainaz
    Akbarzadeh, Shabnam
    Yousefi, Bahman
    Majidinia, Maryam
    LIFE SCIENCES, 2021, 285
  • [26] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
    Glaviano, Antonino
    Foo, Aaron S. C.
    Lam, Hiu Y.
    Yap, Kenneth C. H.
    Jacot, William
    Jones, Robert H.
    Eng, Huiyan
    Nair, Madhumathy G.
    Makvandi, Pooyan
    Geoerger, Birgit
    Kulke, Matthew H.
    Baird, Richard D.
    Prabhu, Jyothi S.
    Carbone, Daniela
    Pecoraro, Camilla
    Teh, Daniel B. L.
    Sethi, Gautam
    Cavalieri, Vincenzo
    Lin, Kevin H.
    Javidi-Sharifi, Nathalie R.
    Toska, Eneda
    Davids, Matthew S.
    Brown, Jennifer R.
    Diana, Patrizia
    Stebbing, Justin
    Fruman, David A.
    Kumar, Alan P.
    MOLECULAR CANCER, 2023, 22 (01)
  • [27] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
    HaiXia Li
    JianFang Zeng
    Keng Shen
    Archives of Gynecology and Obstetrics, 2014, 290 : 1067 - 1078
  • [28] The Cardioprotection of the Insulin-Mediated PI3K/Akt/mTOR Signaling Pathway
    Hong Yao
    Xiangyang Han
    Xiuzhen Han
    American Journal of Cardiovascular Drugs, 2014, 14 : 433 - 442
  • [29] mTOR/PI3k/Akt SIGNALING PATHWAY IN TUMOR ANGIOGENESIS AND THERAPEUTIC TARGETING
    Mabeta, Peace
    Davis, Paul F.
    Pepper, Michael S.
    ANTICANCER RESEARCH, 2014, 34 (10) : 6042 - 6042
  • [30] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080